DRF 10945
Latest Information Update: 07 Jul 2010
At a glance
- Originator Dr Reddys Laboratories
- Developer Perlecan Pharma
- Class Antihyperlipidaemics
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lipid metabolism disorders
Most Recent Events
- 07 Jul 2010 Discontinued - Phase-I for Lipid metabolism disorders in Canada (PO)
- 07 Jul 2010 Discontinued - Preclinical for Lipid metabolism disorders in France (PO)
- 26 May 2009 DRF 10945 is available for licensing (http://www.drreddys.com/investors/pdf/Fiscal2008Form20F.pdf)